JP2018523676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523676A5 JP2018523676A5 JP2018508149A JP2018508149A JP2018523676A5 JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5 JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5
- Authority
- JP
- Japan
- Prior art keywords
- histidine
- hcl
- aniflorumab
- polysorbate
- trehalose dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207164P | 2015-08-19 | 2015-08-19 | |
| US62/207,164 | 2015-08-19 | ||
| PCT/US2016/047506 WO2017031288A1 (en) | 2015-08-19 | 2016-08-18 | Stable anti-ifnar1 formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104494A Division JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523676A JP2018523676A (ja) | 2018-08-23 |
| JP2018523676A5 true JP2018523676A5 (enExample) | 2020-04-23 |
| JP6720293B2 JP6720293B2 (ja) | 2020-07-08 |
Family
ID=58052002
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508149A Active JP6720293B2 (ja) | 2015-08-19 | 2016-08-18 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2020104494A Active JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2022031581A Pending JP2022066345A (ja) | 2015-08-19 | 2022-03-02 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2024140769A Pending JP2024161043A (ja) | 2015-08-19 | 2024-08-22 | 安定な抗ｉｆｎａｒ１製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104494A Active JP7035119B2 (ja) | 2015-08-19 | 2020-06-17 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2022031581A Pending JP2022066345A (ja) | 2015-08-19 | 2022-03-02 | 安定な抗ｉｆｎａｒ１製剤 |
| JP2024140769A Pending JP2024161043A (ja) | 2015-08-19 | 2024-08-22 | 安定な抗ｉｆｎａｒ１製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10125195B2 (enExample) |
| EP (3) | EP3337502B1 (enExample) |
| JP (4) | JP6720293B2 (enExample) |
| KR (4) | KR20240090616A (enExample) |
| CN (2) | CN122424321A (enExample) |
| AU (3) | AU2016308262C1 (enExample) |
| CA (1) | CA2995222C (enExample) |
| CY (2) | CY1123657T1 (enExample) |
| DK (2) | DK3769781T5 (enExample) |
| ES (2) | ES2818229T3 (enExample) |
| FI (1) | FI3769781T3 (enExample) |
| HR (2) | HRP20201297T1 (enExample) |
| HU (2) | HUE061985T2 (enExample) |
| IL (1) | IL257279B2 (enExample) |
| LT (2) | LT3337502T (enExample) |
| PL (2) | PL3337502T3 (enExample) |
| PT (2) | PT3769781T (enExample) |
| RS (2) | RS60773B1 (enExample) |
| RU (1) | RU2731737C2 (enExample) |
| SG (1) | SG10202106970XA (enExample) |
| SI (2) | SI3769781T1 (enExample) |
| SM (2) | SMT202000483T1 (enExample) |
| WO (1) | WO2017031288A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| US20200061015A1 (en) | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| DK4058060T3 (da) * | 2019-11-11 | 2025-03-17 | Astrazeneca Ab | Type i-interferon-hæmning ved systemisk lupus erythematosus |
| JP2023527054A (ja) * | 2020-05-29 | 2023-06-26 | アストラゼネカ・アクチエボラーグ | Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 |
| TWI916375B (zh) | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| JP2023553641A (ja) * | 2020-12-17 | 2023-12-25 | アストラゼネカ アクチボラグ | 抗ｉｌ５ｒ抗体製剤 |
| CN117157099A (zh) * | 2021-04-23 | 2023-12-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
| SMT202300382T1 (it) * | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
| AU2022260544A1 (en) | 2021-04-23 | 2023-11-30 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| TW202317617A (zh) | 2021-04-23 | 2023-05-01 | 瑞典商阿斯特捷利康公司 | 皮膚紅斑狼瘡之治療 |
| CA3219401A1 (en) | 2021-05-12 | 2022-11-17 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
| CN113521276B (zh) * | 2021-07-13 | 2022-04-12 | 江苏荃信生物医药股份有限公司 | 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂 |
| WO2023284073A1 (zh) * | 2021-07-13 | 2023-01-19 | 江苏荃信生物医药股份有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂 |
| AU2022317215A1 (en) | 2021-07-27 | 2024-02-29 | Astrazeneca Ab | Treatment of lupus |
| EP4412641A2 (en) | 2021-10-04 | 2024-08-14 | Astrazeneca AB | Treatment of lupus |
| WO2023073469A1 (en) * | 2021-10-29 | 2023-05-04 | Intas Pharmaceuticals Ltd. | STABLE LYOPHILIZED FORMULATION OF AN ANTI-α4ß7 ANTIBODY |
| WO2023155902A1 (en) * | 2022-02-18 | 2023-08-24 | Chongqing Mingdao Haoyue Biotechnology Co., Ltd. | Intranasal formulations and anti-sars-cov-2-spike protein antibodies |
| WO2024009205A1 (en) * | 2022-07-06 | 2024-01-11 | Intas Pharmaceuticals Ltd. | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY |
| US20260125482A1 (en) | 2022-10-13 | 2026-05-07 | Astrazeneca Ab | Treatment of lupus |
| EP4713361A1 (en) | 2023-05-19 | 2026-03-25 | AstraZeneca AB | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
| CA3251574A1 (en) * | 2024-08-12 | 2026-03-01 | 1000887608 Ontario Inc. | Anti-cancer polypeptides, nucleic acid constructs and methods of using same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5731623A (en) * | 1980-07-30 | 1982-02-20 | Morishita Seiyaku Kk | Production of gamma-globulin for intravenous injection |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| ES2643237T3 (es) * | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| WO2010056804A1 (en) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| MX2014003993A (es) * | 2011-10-12 | 2014-08-08 | Ascendis Pharma Ophthalmology Division As | Prevencion y tratamiento de condiciones oculares. |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| KR20160105535A (ko) * | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US20150239970A1 (en) * | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| US10259842B2 (en) * | 2013-05-15 | 2019-04-16 | Medimmune, Llc | Purification of recombinantly produced polypeptides |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP3062814A1 (en) | 2013-10-29 | 2016-09-07 | Albumedix A/S | Antibody composition |
| CN106604744A (zh) | 2014-09-03 | 2017-04-26 | 免疫医疗有限公司 | 稳定的抗IL‑4R‑α抗体配制品 |
| JP2018500380A (ja) | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス，インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
| SI3769781T1 (sl) | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
-
2016
- 2016-08-18 SI SI201631699T patent/SI3769781T1/sl unknown
- 2016-08-18 EP EP16837818.0A patent/EP3337502B1/en active Active
- 2016-08-18 RU RU2018107725A patent/RU2731737C2/ru active
- 2016-08-18 PL PL16837818T patent/PL3337502T3/pl unknown
- 2016-08-18 LT LTEP16837818.0T patent/LT3337502T/lt unknown
- 2016-08-18 HU HUE20174805A patent/HUE061985T2/hu unknown
- 2016-08-18 EP EP23160045.3A patent/EP4233892A3/en active Pending
- 2016-08-18 JP JP2018508149A patent/JP6720293B2/ja active Active
- 2016-08-18 SG SG10202106970XA patent/SG10202106970XA/en unknown
- 2016-08-18 AU AU2016308262A patent/AU2016308262C1/en active Active
- 2016-08-18 ES ES16837818T patent/ES2818229T3/es active Active
- 2016-08-18 PL PL20174805.0T patent/PL3769781T3/pl unknown
- 2016-08-18 ES ES20174805T patent/ES2947488T3/es active Active
- 2016-08-18 RS RS20201103A patent/RS60773B1/sr unknown
- 2016-08-18 KR KR1020247016705A patent/KR20240090616A/ko active Pending
- 2016-08-18 SM SM20200483T patent/SMT202000483T1/it unknown
- 2016-08-18 DK DK20174805.0T patent/DK3769781T5/da active
- 2016-08-18 SI SI201630900T patent/SI3337502T1/sl unknown
- 2016-08-18 IL IL257279A patent/IL257279B2/en unknown
- 2016-08-18 US US15/240,224 patent/US10125195B2/en active Active
- 2016-08-18 KR KR1020227031079A patent/KR20220127378A/ko not_active Ceased
- 2016-08-18 HU HUE16837818A patent/HUE051862T2/hu unknown
- 2016-08-18 PT PT201748050T patent/PT3769781T/pt unknown
- 2016-08-18 EP EP20174805.0A patent/EP3769781B1/en active Active
- 2016-08-18 CN CN202610400333.6A patent/CN122424321A/zh active Pending
- 2016-08-18 DK DK16837818.0T patent/DK3337502T3/da active
- 2016-08-18 KR KR1020207029325A patent/KR102669174B1/ko active Active
- 2016-08-18 HR HRP20201297TT patent/HRP20201297T1/hr unknown
- 2016-08-18 WO PCT/US2016/047506 patent/WO2017031288A1/en not_active Ceased
- 2016-08-18 HR HRP20230463TT patent/HRP20230463T1/hr unknown
- 2016-08-18 FI FIEP20174805.0T patent/FI3769781T3/fi active
- 2016-08-18 CA CA2995222A patent/CA2995222C/en active Active
- 2016-08-18 RS RS20230447A patent/RS64263B1/sr unknown
- 2016-08-18 LT LTEP20174805.0T patent/LT3769781T/lt unknown
- 2016-08-18 SM SM20230176T patent/SMT202300176T1/it unknown
- 2016-08-18 CN CN201680047012.7A patent/CN107921109B/zh active Active
- 2016-08-18 PT PT168378180T patent/PT3337502T/pt unknown
- 2016-08-18 KR KR1020187007314A patent/KR102168005B1/ko active Active
-
2020
- 2020-05-21 AU AU2020203306A patent/AU2020203306C1/en active Active
- 2020-06-17 JP JP2020104494A patent/JP7035119B2/ja active Active
- 2020-09-11 CY CY20201100860T patent/CY1123657T1/el unknown
-
2021
- 2021-10-26 AU AU2021257915A patent/AU2021257915A1/en not_active Abandoned
-
2022
- 2022-03-02 JP JP2022031581A patent/JP2022066345A/ja active Pending
-
2023
- 2023-06-20 CY CY20231100289T patent/CY1126062T1/el unknown
-
2024
- 2024-08-22 JP JP2024140769A patent/JP2024161043A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EP3316928A4 (en) | AUTOMATIC INJECTORS FOR THE ADMINISTRATION OF A MEDICAMENT IN A PREPARED SYRINGE | |
| HRP20211371T1 (hr) | Stabilne, vodene formulacije protutijela | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| JP2015057451A5 (enExample) | ||
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| JP2015110588A5 (enExample) | ||
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| JP2019516735A5 (enExample) | ||
| EA201891606A1 (ru) | Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| HRP20191137T1 (hr) | Formulacije otopina konstruiranih anti-il-23p19 antitijela | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| JP2016510326A5 (enExample) | ||
| MD20150120A2 (ro) | Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei | |
| PE20170773A1 (es) | Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| JP2016515623A5 (enExample) | ||
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| FI3733712T3 (fi) | Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä | |
| EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
| JP2014058509A5 (enExample) | ||
| EA201890788A1 (ru) | Препараты оланзапина с замедленным высвобождением | |
| JP2016534062A5 (enExample) | ||
| MX383557B (es) | Formulaciones inyectables de paracetamol. |